Press release
HER2+ Gastric Cancer Market Focusing on Trends and Innovations Until 2024 to 2031 | Astrazeneca, Genentech USA, Bristol-Myers Squibb.
HER2+ Gastric Cancer Market || 2024-2031
Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/her2-gastric-cancer-market
What is the projected growth rate (CAGR) of the Global HER2+ Gastric Cancer market from 2024 to 2031?
Global HER2+ Gastric Cancer Market is expected to reach at a Significant CAGR during the forecast period 2024-2031.
The HER2+ Gastric Cancer Market focuses on the treatment and management of gastric cancer characterized by the overexpression of the HER2 protein. HER2-positive gastric cancer is a subtype of gastric cancer that is often more aggressive and resistant to standard therapies. Targeted therapies, such as trastuzumab (Herceptin), and combination treatments that include chemotherapy and HER2-targeted drugs, are key treatment options for this condition. The market is driven by the increasing prevalence of gastric cancer, advancements in targeted therapies, and the growing focus on personalized medicine. Additionally, the rise in early detection and the expanding use of biologics and immunotherapies contribute to the market's growth.
Key Developments:
In November 2023, Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. jointly announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) granted Breakthrough Therapy designation to KN026, a HER2 bispecific antibody, in combination with chemotherapy for the treatment of HER2-positive gastric cancer, including gastroesophageal junction cancer. This designation highlights the potential of KN026 as a promising therapeutic option for patients with this aggressive form of cancer, accelerating its development and regulatory review process.
In December 2022, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) received approval from the European Union (EU) as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have previously received a trastuzumab-based regimen. This approval marks a significant step in providing an additional treatment option for patients with advanced HER2-positive gastric cancer who have limited therapeutic alternatives.
List of the Key Players in the HER2+ Gastric Cancer Market:
Astrazeneca, Genentech USA, Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd, Hutchison Medipharma, LintonPharm, Shanghai Henlius Biotech, Sanofi, Pfizer, Novartis AG and among others.
Research Process:
Both primary and secondary data sources have been used in the global HER2+ Gastric Cancer Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
Segment Covered in the HER2+ Gastric Cancer Market:
By Therapy: Immunotherapy, Chemotherapy, Radiation Therapy, Targeted Therapy.
By Stage: Stage I, Stage II, Stage III, Stage IV.
By End User: Hospitals, Speciality Clinics, Ambulatory Surgical Centers, Others.
Regional Breakout:
The global HER2+ Gastric Cancer Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.
✫ North America (U.S., Canada, Mexico)
✫ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
✫ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
✫ South America (Colombia, Brazil, Argentina, Rest of South America)
✫ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Get Year End Discounts on Premium Report:- https://www.datamintelligence.com/buy-now-page?report=her2-gastric-cancer-market
This Report Unveils:
✔ Go to Market Strategy- A roadmap to successfully product launch or service in the target market.
✔ Gain a clear picture of the market's health and growth trajectory through neutral analysis.
✔ Deep Market Insights delve into development trends, competitor landscape, supply and demand dynamics, brand share & pricing analysis year-over-year growth patterns, and key players' performance.
✔ Upon request, we can provide customized reports focusing on specific regions or countries, offering a granular view of their markets.
✔ Identify high-potential niche segments and regions poised for significant expansion.
✔ Analysis of Market Size (historical and forecast) Total Addressable Market (TAM), Serviceable Available Market (SAM), and Serviceable Obtainable Market (SOM) to understand the market's overall size and your achievable market share.
✔ Gain a comprehensive understanding of the competitive landscape, including market share distribution, key players (innovators, startups, laggards, and pioneers), and their respective strengths and weaknesses.
**The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted**
Chapter Outline:
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: key insights, key emerging trends, etc.
Chapter 3: Manufacturers competitive analysis, detailed analysis of HER2+ Gastric Cancer manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 5 & 6: Revenue of HER2+ Gastric Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the HER2+ Gastric Cancer market in different market segments.
Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the HER2+ Gastric Cancer market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: The main points and conclusions of the report.
Get Customization in the report as per your requirements:- https://datamintelligence.com/customize/her2-gastric-cancer-market
Frequently Asked Questions
☞ What is the expected growth rate of the global HER2+ Gastric Cancer market for the forecast period?
☞ What are the key driving factors that are responsible to shape the fate of the HER2+ Gastric Cancer market during the forecast period?
☞ What will be the overall size of the market during the analysis period?
☞ What are the prominent market trends which influence the development of the HER2+ Gastric Cancer market across various regions?
☞ Who are the key market players and the market strategies that have helped them to secure the leading position in the global market?
☞ What are the challenges and threats that are likely to act as a barrier to the growth of the HER2+ Gastric Cancer market?
☞ What are the major opportunities that the companies can get to attain success in the world?
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HER2+ Gastric Cancer Market Focusing on Trends and Innovations Until 2024 to 2031 | Astrazeneca, Genentech USA, Bristol-Myers Squibb. here
News-ID: 3735085 • Views: …
More Releases from DataM Intelligence 4Market Research
United States Peripheral Neuropathy Market Set for Transformative Growth with Ri …
Market Size and Growth:
The Peripheral Neuropathy Market size was valued US$ 1,539 million in 2021 and is estimated to reach US$ YY million by 2031, growing at a CAGR of 4.2% during the forecast period (2024-2031).
The Peripheral Neuropathy Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants…
United States Acute Coronary Syndrome Market Set for Robust Growth with Advancem …
Market Size and Growth:
The Global Acute Coronary Syndrome Market size reached US$ 9.94 billion in 2023 and is expected to reach US$ 14.70 billion by 2031, growing at a CAGR of 5.1% during the forecast period 2024-2031.
The Acute Coronary Syndrome Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for…
United States Atrial Fibrillation Market Surges with Breakthrough Therapies and …
Market Size and Growth:
The Global Atrial Fibrillation Market size reached US$ 26.75 billion in 2024 and is expected to reach US$ 63.79 billion by 2033, growing at a CAGR of 10.6 % during the forecast period 2025-2033.
The Atrial Fibrillation Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market…
United States Personalized Cancer Vaccines Market Set for Breakthrough Growth wi …
Market Size and Growth:
The Global Personalized Cancer Vaccines Market size reached US$ 11.33 Billion in 2024 from US$ 10.21 Billion in 2023 and is expected to reach US$ 30.12 Billion by 2033, growing at a CAGR of 11.5% during the forecast period 2025-2033.
The Personalized Cancer Vaccines Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in…
More Releases for HER2
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously wor …
DelveInsight's HER2 negative Breast Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain.
Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report:
• DelveInsight's HER2 negative Breast Cancer Pipeline analysis depicts a robust space with…
